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Abstract
Background: Infection after osteosynthesis is an important complication with significant morbidity and even
mortality. These infections are often caused by biofilm-producing bacteria. Treatment algorithms dictate an
aggressive approach with surgical debridement and antibiotic treatment. The aim of this study is to analyze the
effect of such an aggressive standardized treatment regime with implant retention for acute, existing <3 weeks,
infection after osteosynthesis.
Methods: We conducted a retrospective 2-year cohort in a single, level 1 trauma center on infection occurring
within 12 months following any osteosynthesis surgery. The standardized treatment regime consisted of implant
retention, thorough surgical debridement, and immediate antibiotic combination therapy with rifampicin. The
primary outcome was success. Success was defined as consolidation of the fracture and resolved symptoms
of infection. Culture and susceptibility testing were performed to identify bacteria and resistance patterns.
Univariate analysis was conducted on patient-related factors in association with primary success and antibiotic
resistance.
Results: Forty-nine patients were included for analysis. The primary success rate was 63% and overall
success rate 88%. Factors negatively associated with primary success were the following: Gustilo classification
(P = 0.023), higher number of debridements needed (P = 0.015), inability of primary closure (P = 0.017), and
subsequent application of vacuum therapy (P = 0.030). Adherence to the treatment regime was positively related to
primary success (P = 0.034).
Conclusions: The described treatment protocol results in high success rates, comparable with success rates achieved
in staged exchange in prosthetic joint infection treatment.
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Background
Infection after surgical treatment of fractures is a com-
plication with significant morbidity and in rare cases
even mortality [1, 2]. Consequences of infections include
delayed or non-union of the fracture [3]. Infections that
occur following osteosynthesis are typically caused by
biofilm-forming bacteria, which adhere to the foreign
body material [4]. After 3 weeks, a mature biofilm is
formed, which makes it impossible to eradicate bacteria
by antibiotics alone [5]. Most research in this field
focuses on peri-prosthetic infection, despite of the
different treatment challenges in prosthetic surgery and
osteosynthesis. Treatment algorithms have been devel-
oped, which dictate aggressive debridement, antibiotic
treatment, and if necessary staged replacement of the
prosthetic material [4, 6].
Common treatment for peri-prosthetic infection con-
sists of three pillars: surgical debridement, antibiotic
therapy, and implant removal or staged change.
However, in osteosynthesis, implant removal is unfavor-
able because of the recurrence of fracture instability
which is related to protracted infection and inability to
resolve infection [7, 8]. This has consequences for the
other aspects of treatment: as the implant stays in place,
the biofilm does too. Surgical debridement can remove a
gross part, but antibiotic therapy must be adjusted to the
presence of a biofilm.
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For this reason, in our hospital, a standardized treat-
ment regime was introduced, with the intention to treat
the infection with implant retention until fracture
healing is achieved. This regime consists of thorough
surgical debridement, tissue cultures, and long-term anti-
biotic combination therapy with rifampicin. Rifampicin
was chosen because of its high bioavailability and penetra-
tion into biofilms [9].
Soft tissue damage and wound coverage causes
additional difficulties for the healing process during
infection after osteosynthesis. For the latter, flap cover
or vacuum therapy are the preferred choices within
our hospital.
The aim of this study was to analyze the success rate
of patients with infection after osteosynthesis undergo-
ing surgical debridement, tissue cultures, and long-term
antibiotic combination therapy with rifampicin.
Methods
Study design and population
This was a retrospective cohort study, with a level of evi-
dence therapeutic level IV. Patients treated for early and
delayed (<12 months) infection after osteosynthesis in a
level 1 trauma center were analyzed [4]. Included pa-
tients were between 18 and 80 years of age and treated
for infection following osteosynthesis from the introduc-
tion of the regime in January 2011 until September
2013. Subjects were identified in the operation register.
All acute infections following osteosynthesis were
included, independent of localization, implant used, or
Gustilo classification. Infections following prosthetic sur-
gery and revision arthroplasties were excluded. Subjects
in whom symptoms (e.g., redness, drainage from surgical
wound, fever, pain, elevated CRP, or leukocytes) had
existed for longer than 3 weeks, thus with matured bio-
film, were excluded [5]. Also, patients with consolidated
fractures at presentation of infection were excluded, here
implant removal was considered to be the appropriate
treatment. Patient characteristics were collected from
electronic patient files. Extracted data are listed in the
baseline characteristics.
Treatment
All patients included in the study were treated by initial
thorough surgical debridement of affected soft tissue and
necrotic bone during which deep tissue cultures were ob-
tained. Surgical debridement was repeated as often as
needed. When primary closure could not be performed,
continuous applied vacuum therapy (VAC®System) was
applied to provide temporary covering and improve sec-
ondary wound healing. Small, non-infected skin defects
are left untreated but are considered “open” in this study
with respect to time to closure. In case of large soft tissue
damage, skin transplant or free flaps were to be
considered. Only when infection persisted despite multiple
surgical debridements without the prospect of infection
control, implant removal was considered, and alternative
form of stability at the fracture site was initiated.
Antibiotic combination therapy started immediately
after the first surgical intervention and consisted of
10 days of intravenous (i.v.) vancomycin and rifampicin
(Fig. 1). Vancomycin was the agent of choice for empir-
ical therapy because of its activity against a broad
spectrum of microorganisms, high incidence of Gram
positive (e.g., Staphylococcus aureus) infections, and the
synergetic effect with rifampicin [10–13]. Vancomycin
therapy was started as twice daily 1000 mg i.v. and was
adjusted to maintain serum levels between 15 and
20 mcg/ml. Rifampicin was given twice daily 450 mg i.v.
Rifampicin was added because of its relatively easy pene-
tration into biofilm, its high bioavailability, and its ability
to affect organisms in stationary growth phase [9, 14–19].
When tissue cultures grew bacterial pathogens and sus-
ceptibility data were available, vancomycin therapy was
switched to another, narrower spectrum, antibiotic as indi-
cated by the treating physician. Rifampicin was continued
unless rifampicin-resistant bacteria were found. After the
intravenous administration period, oral combination
antibiotic therapy with rifampicin was continued for ten
additional weeks [4].
Treatment was considered to be in accordance with
the regime if there were no or minor deviations, in line
with clinical practice. Here, minor deviation was defined
as deviation of duration of antibiotic therapy or when
tissue or swab cultures were not adequately obtained.
Major deviation from the regime consisted of no surgical
debridement, initial implant removal, no or inadequate
oral or intravenous antibiotic therapy, or monotherapy
with rifampicin.
Subjects were followed in the outpatient clinic for at
least 3 months or until fracture consolidation and infec-
tion control were achieved.
Patient identification
In total, 80 patients with infection or osteomyelitis after
osteosynthesis were identified. Twenty-one patients were
excluded after thorough review (Fig. 2). Patients who
have had symptoms for over 3 weeks (not acute) were
excluded from final analysis (n = 10). The remaining 49
(60%) patients were eligible for analysis (Table 1). The
median age is 45 years (range 18–69), and the majority is
of male gender (76%). Infection was mainly of pelvic ring,
femur, and tibia (67% combined), and in 11 (22%) cases, it
concerned complicated fractures (Gustilo IIIA-IIIC).
Plates and nails were the most often used implants. Ninety
percent of the infections manifested in the first 3 months
after osteosynthesis or last surgery related to the trauma
on the respective body part. Overall, adherence to the
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regime increased over time from 75% at the time of intro-
duction to 100% in 2013 (Table 1).
Microbiology
From all subjects, peri-operative cultures (tissue, swab,
fluid) were obtained during initial surgical debridement
and were repeated with every additional surgery. Isolates
were cultured and identified using standard techniques
until growth and identification was apparent or to a max-
imum of 6 days in case of negative culture. Susceptibility
testing was performed on isolates using Phoenix auto-
mated susceptibility testing, disk diffusion, and/or E-test.
Study endpoints
The primary endpoint was success. Primary success was
defined as consolidation of the fracture on X-ray and
clinical examination, as assessed by the treating phys-
ician, resolved clinical signs and symptoms of infection
after completion of the standardized treatment regime.
Consolidation is defined as ossified callus bridging ≥3
cortices on radiography and stable and painless bone at
attempted angulation on examination. Since this was a
retrospective analysis with a variety of types of fractures
and fracture sites, covering all grades of the AO- and
Gustilo classification, no strict timeframe or routine la-
boratory follow-up was available. Secondary success was
defined as consolidation of the fracture with no signs of
infection after a prolongation of the standardized treat-
ment regime or delayed implant removal (Fig. 1). Time
to secondary success was described. Any other outcome
than primary or secondary success was considered treat-
ment failure. A univariate analysis was performed to
Fig. 1 A flow scheme of the standardized treatment regime as executed in our hospital
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identify factors associated with treatment failure, e.g.,
type of fracture, variation in treatment (surgical and/or
microbial), and patient characteristics. Overall success
was the primary and secondary success combined.
The microbial characteristics of the infections, the
proportion of infections caused by vancomycin- and
rifampicin-susceptible microorganisms, and possible fac-
tors influencing incidence of resistance were identified.
Statistical analysis
Primary endpoints, primary and secondary success, were
descriptive. Concerning secondary endpoints, non-
parametric test were applied. A univariate analysis was
conducted. Due to the limited number of cases, a multi-
variate analysis was not applicable. In the univariate ana-
lysis, association was determined using Fisher’s exact
test for dichotomous variables, linear-by-linear for
nominal, and Mann-Whitney U for continuous data.
P values <0.05 are considered as significant.
Results
Study population
Primary closure after initial debridement could be per-
formed in 47% of the patients. In the remaining, closure
was achieved through secondary wound healing with or
without vacuum therapy, skin or free flap transplant-
ation. Time to delayed skin closure, including small
communicating defects despite transplantation, demon-
strated a median closure time of 85 days, with outliers
up to 540 days. Forty-seven patients were treated with
intravenous combination therapy, for a median duration
of 10 days, range 3–116 days. The 2 patients who did
not receive intravenous antibiotic therapy did not dem-
onstrate signs of infection surrounding the implant dur-
ing surgical debridement or infection had not reached
the fracture site. The decision was made to treat as
superficial wound infection. Of the patients who did not
get rifampicin, 4 had implant removal, 1 had only one
screw in situ, 2 patients had the entire antibiotic therapy
ceased because of low suspicion of deep infection. In 1
patient, rifampicin therapy was stopped because of inter-
action with psychiatric drugs. The entire antibiotic ther-
apy had duration with a median of 80 days, ranging
from 0 to 126 days. Antibiotic agents used in the intra-
venous combination therapy were most often vanco-
mycin, rifampicin, and ciprofloxacin. Oral agents were
predominantly rifampicin and flucloxacillin.
Success
Primary success after completion of standardized treatment
regime was reached in 63% of the patients after a median
duration of 4 months (range 1–13 months). Of the patients
who primarily succeeded, 90% was treated according to the
regime or had only minor deviation. Statistical significance
with a negative association toward the primary success
group were found for higher Gustilo classification
(≥II) (P = 0.023), higher number of debridements per-
formed (P = 0.015), impossibility of primary closure
(P = 0.017), and in line with this the necessity for vacuum
dressing after debridement (P= 0.030). A statistical significant
positive association was found when patients were treated ac-
cording to the regime (P= 0.025). A shorter duration of oral
antibiotic therapy (P= 0.033) than specified in the standard-
ized treatment regime was negatively related (Table 1).
Fig. 2 Patient identification and inclusion
Hellebrekers et al. Journal of Orthopaedic Surgery and Research  (2017) 12:41 Page 4 of 11
Secondary success was achieved in 12 of the 18
remaining patients in whom success was not reached
after completion of a single run. Secondary success was
achieved after a median duration of 14 months (range
6–24 months). Of those with secondary success, 11
patients demonstrated persisting or relapsing symptoms
of inflammation at the infection site before consolidation
occurred. Four were treated with implant removal and
Table 1 Baseline characteristics and the association with primary cure
Variable Baseline Primary success rate P value
(n = 49) No (n = 18) Yes (n = 31)
Patient
Age, years 45 (18–69) 47 (25–66) 45 (18–69) 0.194
Male gender 37 13 24 0.738
Smoking 20 10 10 0.226
Comorbidities
Diabetes mellitus 5 1 4 0.639
Psychiatric disorder 14 6 8 0.744
BMI 26.3 (19.5–41.8) 26.3 (19.5–41.8) 26.3 (20.2–38.5) 0.719
Oral corticosteroid use 1 – 1 1.0
Follow-up, months 12 (3–36) 19 (8–32) 10 (3–36) 0.008
Fracture
Localization 0.140
Sternum/costa 2 1 1
Humerus 1 – 1
Radius/ulna 4 2 2
Pelvic ring 11 2 9
Femur 8 3 5
Tibia/fibula 14 8 6
Ankle 6 – 6
Foot 3 2 1
Type 0.023
Closed 28 6 22
Open Gustilo classification
I 6 2 4
II 3 2 1
IIIA 4 4 –
IIIB 4 1 3
IIIC 3 2 1
AO classification 0.144
A 4 0 4
B 13 4 9
C 25 10 15
Not applicable 7
Type of osteosynthesis 0.649
(Cerclage) wires 1 – 1
Screws 6 2 4
Nail 12 6 6
Plate 30 10 20
Data are presented as the number of cases with the percentage in parenthesis or as median with the range in parenthesis
i.v. intravenous
P values of <0.05 are considered significant. Only P values of <0.05 are in italic
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repeated antibiotic therapy, 4 only with implant removal,
and 3 only with repeated antibiotic therapy. Only in 1
patient the reason of primary failure was non-union of
the fracture, in which success was reached after revision
osteosynthesis. When primary and secondary success
rates were combined, this results in an overall success
rate of 88% (Table 2).
Of the patients in whom success was not reached, all
but one had diminished signs and symptoms of infec-
tion, yet without consolidation of the fracture. One
patient still had persisting infection at the moment of
analysis (Table 3).
Microbiology
Of the 49 included cases, in one case, no tissue samples
were obtained for culture and 5 had shown no growth at
first culture, despite intraoperative signs of infection. In
16 of the cases, only S. aureus could be cultured from
the samples retrieved, in all but one case it concerned
methicillin-susceptible S. aureus. In 2 cases, solely
coagulase-negative staphylococci (CoNS), and in 4 cases,
other single organisms were cultured (Enterococcus
faecalis, Streptococcus dysgalactiae, Enterobacter cloacae
complex, Enterobacter gergoviae) (Table 1). In the
remaining 21 cases, culture showed mixed microorgan-
isms, of which in 48% it included S. aureus, all methicil-
lin susceptible. Based on first culture, the choice of
empirical treatment with rifampicin and vancomycin
was adequate in 88 and 91% of the cases, respectively
(Table 4).
Vancomycin and rifampicin resistance
No vancomycin resistance was demonstrated in any of
the cases. Rifampicin resistance at first culture was
Table 2 Infection and treatment characteristics and association with primary cure
Variable Baseline Primary success rate P value
(n = 49) No (n = 18) Yes (n = 31)
Infection
Type of infection 0.260
Early 44 15 29
Delayed 5 3 2
Microorganism
Negative culture 5 1 4 0.623
Staphylococcus aureus 16 6 10 1.0
CoNS 2 1 1 1.0
Polymicrobial culture 21 10 11 0.206
Other single microorganism 4 – 4 0.282
Rifampicin resistance at first culture 3 2 1 0.544
Rifampicin resistance in all cultures 8 5 3 0.250
Treatment
Number of debridements performed 2 (0–14) 3 (0–14) 2 (1–5) 0.015
Closure
Primary closure 23 4 19 0.017
VAC therapy after debridement 17 10 7 0.030
Time to closure after debridement, days 157 (8–700) 271 (38–700) 149 (8–157) 0.000
Antibiotic therapy
Duration i.v. antibiotic therapy 10 (0–116) 14 (0–77) 10 (0–116) 0.203
Duration oral antibiotic therapy 70 (0–112) 63 (0–89) 70 (0–112) 0.033
Duration total antibiotic therapy 80 (0–126) 80 (0–126) 81 (9–116) 0.186
Duration of rifampicin therapy 80 (5–116) 75 (6–97) 80 (5–116) 0.118
NSAID use during treatment 36 14 31 0.743
Treated according to protocol 0.025
Yes 39 11 28
No 10 7 3
Data are presented as the number of cases with the percentage in parenthesis or as median with the range in parenthesis
i.v. intravenous
P values of <0.05 are considered significant. Only P values of <0.05 are in italic
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demonstrated in 3 (6%) cases, all CoNS, one proven to
be Staphylococcus epidermidis. In 18 cases, no follow-up
tissue sample or swabs were taken. Twenty-two out of
the 30 follow-up cultures grew microorganisms.
Rifampicin resistance was demonstrated in 7 cultures, of
which 2 overlapped with resistance at first culture. In
the 5 new cases, S. aureus (methicillin-susceptible S.
aureus; MSSA) was seen once, and in 4 cases, S.
epidermidis was demonstrated.
Rifampin resistance was significantly more frequently
found after secondary than after primary closure of the
wound (P = 0.044) (Table 3). Secondary closure was
associated with longer duration of intravenous antibiotic
therapy (P = 0.008). No association was found between
rifampicin resistance and primary (P = 0.250) or overall
success (P = 0.580) (Table 5).
Discussion
The aim of the study was to evaluate the effect of a stan-
dardized treatment regime for acute infection after
osteosynthesis. Results demonstrate a high success rate,
especially when patients are treated strictly according to
the regime or with only minor deviations, resulting in an
overall success rate of 88%. In almost all patients,
Table 3 Overview of patients without success
Patient no. Follow-up (mo) Fracture, Gustilo Closure MB Rifampicin
resistance
Treatment Failure reason











3 16 Distal femur, IIIC Split skin
graft
PM No Multiple surgical debridement
and antibiotic therapy, local
antibiotic therapy, removal OSM
Non-union, persisting low
grade infection
4 15 Shaft tibia/fibula, IIIB Free flap CoNS Yes Masquelet technique, surgical
debridement, no intravenous
antibiotic therapy, when relapse
adequate protocol treatment
Non-union
















mo months, MB microbiology, PM polymicrobial, CoNS coagulase-negative Staphylococci, NG no growth, OSM osteosynthetic material, NA not applicable
Table 4 Microbiological characteristics of included cases






No growth 5 (10%) 80 80 – –
Staphylococcus aureus 16 (33%) 63 88 100 100
MSSA 15 (94%)
MRSA 1 (6%)
Coagulase-negative staphylococci 2 (4%) 50 100 100 100
Polymicrobial infectionsb 21 (43%) 52 86 86 91
Other single microbial infectionsc 4 (8%) 100 100 25 50
Rifampicin resistance at first culture 3 (6%) Overall susceptibility 88 91
MSSA methicillin-susceptible Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus
aEmpirical therapy is considered adequate when first culture obtains one or more susceptible pathogenic microorganisms
b10 cultures contained S. aureus among others
cSingle microorganisms were cultured, concerning Streptococcus dysgalactiae, Enterobacter cloacae complex, Enterobacter gergoviae, and Enterococcus faecalis
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implants could be retained until fracture consolidation
was achieved. We found a negative association between
the achievement of primary success and Gustilo classifi-
cation, necessary number of debridements, inability of
primary closure after debridement, and subsequent ap-
plication of vacuum therapy. In case of treatment failure,
all but one subject had infection control, but lacked frac-
ture consolidation, one case had a persisting infection at
the moment of analysis.
There are only a limited number of studies on the out-
come after combination therapy with rifampicin for in-
fection after osteosynthesis in an in vivo setting. Data
available for comparison mostly refer to prosthetic joint
infection (PJI). The reported success rate of PJI treated
with antibiotic combination therapy with rifampicin var-
ies widely. Zimmerli et al. as well as Barberan et al. and
Drancourt et al. studied infection following osteosynth-
esis and the effect of antibiotic combination therapy with
rifampicin [20–22]. They analyzed both PJI and osteo-
synthesis treated with initial implant retention and com-
bination antibiotic therapy and found a success rate of
48% after an average follow-up of 23.5 months. The
study of Barberan et al. solely included patients with
osteosynthesis and found a success rate of 72% [21].
Notably, they only performed surgical debridement in
72% of the cases. In contrast, Zimmerli et al. studied ri-
fampicin combination therapy for infection associated
with orthopedic implants, combining prosthetic surgery,
and osteosynthesis and showed a 100% success rate in
the rifampicin combination group [20]. Additionally, a
recent study showed high success rates (90%) with the
use of rifampicin in staphylococci-positive infections. In
contrast with our study, they handled strict selection cri-
teria for patients to be treated according to their algo-
rithm, whereas we included all patients in spite of the
condition of the soft tissue or found pathogens [23].
Other treatment regimens for infection following osteo-
synthesis with retention of the implant are proposed
without rifampicin combination therapy. For example
by Aytac et al., they propose a treatment containing of
thorough surgical debridement with insertion of a persist-
ing fistula and antibiotic treatment (4–8 weeks). They ac-
complish comparable promising success rates. However,
they excluded subjects with mild to extensive soft tissue
injury, sepsis, and re-occurrence of infection >1 year.
Whereas we included all acute infections to optimize the
reflection of current clinical practice [24].
We carried out a regimen in which implant retention
was one of the objectives for all patients. In contrast, treat-
ment guidelines for PJI only consider patients who are
presented within 30 days after prosthesis implantation for
retention of prosthesis strategy [6]. Implant removal is not
desirable in case of acute infection as osteosynthesis serves
two different goals. First, the stability achieved by fixation
is critical for fracture healing [22, 25]. When conditions
are created in which (micro-)motion between bone frag-
ments is possible, resorption and necrosis of affected bone
will occur [8]. Secondly, the aim of operative fracture
management and early mobilization is to prevent loss of
function due to scarring of the surrounding soft tissue or
joint stiffness [26]. Special consideration should be given
to infection after intramedullary fixation, the common
stand is that diagnosis of the infected medulla and eradi-
cation of the infection is not feasible without implant ex-
change (Fig. 3) [27]. However, no international consensus
is reached and other studies describe good cure rates with
retention of the implant and propose treatment algo-
rithms with nail retainment in early and delayed infections
[28]. In this study, we subjected these patients to the same
regime and we aimed to retain the implant in all. If the
implant is to be removed, immobilization of the affected
body part is required, with loss of function as a result [26].
Whereas removal or exchange of the implant provides the
opportunity to remove the biofilm and as a result signifi-
cantly reduce the bacterial load, and in case of implant re-
tention, the surgical debridement and antibiotic therapy
play a more important role. Combined, these different
approaches make it difficult to compare outcome of infec-
tion after osteosynthesis with outcome after prosthetic
joint infection.
Rifampicin is a potent antibiotic for the treatment of
infections with biofilm-forming bacteria, which is a
common cause for infection after osteosynthesis. The
consequence of the increasing use of rifampicin is the
emergence of resistance to this antibiotic and the occur-
rence of cross-resistance [11, 29]. In vivo studies give in-
dications for emergence of resistance in cases with
inadequate surgical debridement and/or high bacterial
load [5]. We found a significant difference in rifampicin
resistance between patients with primary closure follow-
ing surgical debridement and patients with secondary
closure, skin transplant, or free flap, with a higher fre-
quency of resistance in the latter. This can be explained
Table 5 Association between closure after surgical debridement
and overall rifampicin resistance
Overall rifampicin resistance P value




Primary closure 18 1
Secondary closure or free flap 13 7
Time to closurea, median
days (range)
127 (38–540) 117 0.253
Primary success 20 3 0.250
Overall success 28 6 0.580
aCases with primary closure are excluded
P values of <0.05 are considered significant. Only P values of <0.05 are in italic
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by the fact that open wounds are constantly re-
contaminated with (commensal) skin flora and there is a
selection of, intrinsically, resistant mutants.
Another factor that can be of significance with regard
to wound- and bone healing in our cohort is the pres-
ence of comorbidities. Although this typical trauma co-
hort consist mainly of young, psychically healthy adults,
comorbidities such as psychiatric disorders and charac-
teristics as smoking were abundant and may have
contributed to impaired healing [30, 31].
Furthermore, having an open wound or bad soft tissue
condition may maintain infection, prolonging the neces-
sity for antibiotic therapy; and thereby, the exposure of
microorganisms to rifampicin and emergence to rifampi-
cin becomes more opportune. However, in this study,
total duration of the administration of rifampicin did not
differ between the primary and secondary closure group.
The limitations to this study were inherent to the retro-
spective character. There was neither the aimed homogen-
eity in treatment approach, nor in follow-up or strictly
defined objective outcome measures (e.g., laboratory data,
time frame). Due to the limited number of cases included,
a multivariate analysis could not be conducted. Thereby,
no statements could be made on independent risk factors
for initial failure of the standardized treatment regime.
Additionally, we included all acute infections after
osteosynthesis, creating a heterogeneous group of
Gustilo classification, affected body part, and choice of
internal fixation adding up to the difficulty to assign re-
sults to specific elements. However, considering the low
overall incidence of 1–2% for infection following osteo-
synthesis, it is not feasible to form a cohort with a
homogeneous population, concerning fracture and im-
plant type.
Another drawback is the fact that there was a fair
amount of variation within the treatment regime.
However, we wanted to show the real-time results of a
standardized treatment, and in that way present current
practice.
Due to the fact that we analyzed a single cohort from
one, level 1 trauma center, one may argue that the re-
sults found in this study could not be generalized. Yet,
since we are a specialized center, also patients from level
2 and 3 centers were referred and included. In addition,
open fractures, seen more in multi-trauma patients, are
known to be at higher risk to develop infection.
Fig. 3 Example of an infection after intramedullary osteosynthesis for a tibial shaft fracture (AO42-C2). 1 At presentation at the emergency
department. 2 After nailing, the fracture was accompanied by a compartment syndrome treated with fasciotomy. 3 Patient presented on the
emergency department with redness, swelling, and elevated CRP and leukocytes 7 months after initial osteosynthesis. The patient was admitted,
and a thorough surgical debridement was performed immediately, the nail was left in situ. Intraoperative tissue cultures were obtained, and
empirical antibiotic combination therapy was started. 4 Six months later, the fracture showed bridging of three cortices on X-ray and all signs
and symptoms of infection were diminished. The patient visited the outpatient clinic 2 years later for an unrelated issue. The leg was entirely
healed without pain with full weight bearing and full range of motion. The nail was never removed
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Moreover, lacking a control group, no comparison
could be drawn with results in patients treated according
to a different protocol. However, this is the first series to
describe outcome of standardized aggressive treatment
for infection after osteosynthesis, consisting of implant
retention, thorough surgical debridement, and intensive
antibiotic combination therapy with rifampicin.
Conclusions
This study demonstrates an acceptable success rate in a
clinical challenging problem of infection after osteosynth-
esis by a standardized treatment regime using aggressive
surgical debridement and immediate broad combination
antibiotic therapy. Further comparison studies and ran-
domized trials are needed to evaluate this concept.
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